• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Dosing of ranibizumab maintains visual acuity improvements


Two-year results of an exploratory study using an optical coherence tomography-guided variable dosing regimen with ranibizumab in patients with age-related macular degeneration showed that patients maintained visual acuity improvements achieved after an initial series of three monthly injections.

Key Points

Two-year outcomes of the PrONTO study (Prospective Optical coherence tomography imaging of patients with Neovascular AMD Treated with intra-Ocular ranibizumab) showed that improvements in OCT and VA occurred rapidly, with the OCT changes typically preceding the acuity changes.

The strategy of tailoring treatment based on individual patient need, with need defined by fluid on the OCT, was successful in this group of 40 patients, said Philip J. Rosenfeld, MD, PhD, who pre sented findings here at the annual meeting of the Retina Society. He is professor of ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami.

He added that, although the average cumulative injection rate calculated at the end of the study was every 3 months, some patients were receiving injections every 2 months, and others were receiving them every 3 or 4 months.

Individualized treatment

Related Videos
© 2024 MJH Life Sciences

All rights reserved.